Towerview LLC Sells 40,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Towerview LLC lowered its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 34.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,500 shares of the company’s stock after selling 40,000 shares during the quarter. Corvus Pharmaceuticals accounts for about 0.3% of Towerview LLC’s holdings, making the stock its 19th largest position. Towerview LLC’s holdings in Corvus Pharmaceuticals were worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Corvus Pharmaceuticals by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after buying an additional 102,869 shares in the last quarter. State Street Corp raised its holdings in shares of Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after buying an additional 57,943 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth approximately $265,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Corvus Pharmaceuticals by 441.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock worth $262,000 after buying an additional 40,404 shares in the last quarter. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $3.94 on Friday. The stock has a fifty day moving average of $5.08 and a 200-day moving average of $6.05. The stock has a market capitalization of $253.17 million, a P/E ratio of -4.24 and a beta of 1.07. Corvus Pharmaceuticals, Inc. has a 52 week low of $1.30 and a 52 week high of $10.00.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CRVS. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th. Oppenheimer raised their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.